RU2019132074A - Новая аморфная дисперсия (5-{ 5-[n'-(2-хлор-6-метилбензоил)гидразинокарбонил]-2-метил-фенилэтинил} -пиридин-2-ил)амида циклопропанкарбоновой кислоты - Google Patents
Новая аморфная дисперсия (5-{ 5-[n'-(2-хлор-6-метилбензоил)гидразинокарбонил]-2-метил-фенилэтинил} -пиридин-2-ил)амида циклопропанкарбоновой кислоты Download PDFInfo
- Publication number
- RU2019132074A RU2019132074A RU2019132074A RU2019132074A RU2019132074A RU 2019132074 A RU2019132074 A RU 2019132074A RU 2019132074 A RU2019132074 A RU 2019132074A RU 2019132074 A RU2019132074 A RU 2019132074A RU 2019132074 A RU2019132074 A RU 2019132074A
- Authority
- RU
- Russia
- Prior art keywords
- dosage form
- amorphous dispersion
- solid dosage
- oral solid
- hydrazinocarbonyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (8)
1. Пероральная твердая лекарственная форма, содержащая смесь соединения Формулы I
и плавкого полимерного носителя; и,
возможно, фармацевтически приемлемые эксципиенты, где данная смесь представляет собой аморфную дисперсию.
2. Пероральная твердая лекарственная форма по п. 1, в которой плавкий полимерный носитель представляет собой привитой сополимер поливинилкапролактама-поливинилацетата-полиэтиленгликоля.
3. Пероральная твердая лекарственная форма по п. 2, в которой аморфная дисперсия находится в размельченной форме, где все частицы имеют размер менее 500 микрометров.
4. Пероральная твердая лекарственная форма по п. 1, в которой массовое отношение плавкого полимерного носителя к соединению Формулы I составляет примерно 7:1.
5. Пероральная твердая лекарственная форма по п. 3, где данная лекарственная форма представляет собой капсулу, заполненную аморфной дисперсией и фармацевтически приемлемым эксципиентом.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201721005409 | 2017-03-15 | ||
IN201721005409 | 2017-03-15 | ||
PCT/IN2018/050147 WO2018167803A1 (en) | 2017-03-15 | 2018-03-15 | Novel amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[ n'-(2-chloro-6-methylbenzoyl) hydrazinocarbonyl] -2-methyl-phenylethynyl}-pyridin-2-yl) amide |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019132074A true RU2019132074A (ru) | 2021-04-15 |
RU2019132074A3 RU2019132074A3 (ru) | 2021-07-13 |
RU2768887C2 RU2768887C2 (ru) | 2022-03-25 |
Family
ID=63521905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019132074A RU2768887C2 (ru) | 2017-03-15 | 2018-03-15 | Новая аморфная дисперсия (5-{ 5-[n'-(2-хлор-6-метилбензоил)гидразинокарбонил]-2-метил-фенилэтинил} -пиридин-2-ил)амида циклопропанкарбоновой кислоты |
Country Status (9)
Country | Link |
---|---|
US (1) | US11273126B2 (ru) |
EP (1) | EP3596049A4 (ru) |
JP (1) | JP7234128B2 (ru) |
CN (1) | CN110506036A (ru) |
AU (1) | AU2018235447B2 (ru) |
CA (1) | CA3056356A1 (ru) |
MA (1) | MA47798A (ru) |
RU (1) | RU2768887C2 (ru) |
WO (1) | WO2018167803A1 (ru) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX343042B (es) * | 2005-12-23 | 2016-10-21 | Ariad Pharma Inc | Compuestos heteroarilicos biciclicos. |
KR20090018104A (ko) * | 2006-05-08 | 2009-02-19 | 어리어드 파마슈티칼스, 인코포레이티드 | 아세틸렌계 헤테로아릴 화합물 |
JP2010509289A (ja) * | 2006-11-09 | 2010-03-25 | アボット ゲーエムベーハー ウント コンパニー カーゲー | チロシンキナーゼ阻害剤の経口投与用薬学的剤形 |
AU2010208480A1 (en) * | 2009-02-02 | 2011-07-28 | Msd K.K. | Inhibitors of Akt activity |
JP5868414B2 (ja) * | 2010-11-08 | 2016-02-24 | カディラ ファーマシューティカルズ リミテッド | タキソイドの医薬組成物 |
EA024194B8 (ru) * | 2011-01-21 | 2016-11-30 | Сан Фарма Адвансед Ресьорч Компани Лтд | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы |
DK3181128T3 (da) * | 2012-01-13 | 2023-06-06 | Xspray Pharma Ab Publ | Farmaceutisk nilotinib-sammensætning |
US8859541B2 (en) * | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
ES2670601T3 (es) * | 2012-05-15 | 2018-05-31 | Novartis Ag | Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1 |
CN103664787B (zh) * | 2012-09-17 | 2015-09-09 | 南京圣和药业股份有限公司 | 炔杂芳环化合物及其应用 |
EP2913048A1 (en) * | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Pharmaceutical composition comprising trametinib |
TWI718102B (zh) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | 4環性化合物的非晶質體 |
US10150733B2 (en) * | 2015-05-18 | 2018-12-11 | Sun Pharma Advanced Research Company Ltd. | Amidoheteroaryl aroyl hydrazide ethynes |
-
2018
- 2018-03-15 AU AU2018235447A patent/AU2018235447B2/en active Active
- 2018-03-15 RU RU2019132074A patent/RU2768887C2/ru active
- 2018-03-15 WO PCT/IN2018/050147 patent/WO2018167803A1/en unknown
- 2018-03-15 CA CA3056356A patent/CA3056356A1/en not_active Abandoned
- 2018-03-15 JP JP2019550640A patent/JP7234128B2/ja active Active
- 2018-03-15 MA MA047798A patent/MA47798A/fr unknown
- 2018-03-15 US US16/494,598 patent/US11273126B2/en active Active
- 2018-03-15 EP EP18768528.4A patent/EP3596049A4/en not_active Withdrawn
- 2018-03-15 CN CN201880018613.4A patent/CN110506036A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3056356A1 (en) | 2018-09-20 |
US11273126B2 (en) | 2022-03-15 |
AU2018235447A1 (en) | 2019-10-03 |
RU2768887C2 (ru) | 2022-03-25 |
WO2018167803A1 (en) | 2018-09-20 |
JP7234128B2 (ja) | 2023-03-07 |
MA47798A (fr) | 2020-01-22 |
RU2019132074A3 (ru) | 2021-07-13 |
JP2020510064A (ja) | 2020-04-02 |
EP3596049A1 (en) | 2020-01-22 |
EP3596049A4 (en) | 2021-01-13 |
CN110506036A (zh) | 2019-11-26 |
WO2018167803A9 (en) | 2019-02-28 |
AU2018235447B2 (en) | 2021-12-09 |
US20210113470A1 (en) | 2021-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
JP2016512248A5 (ru) | ||
JP2013505205A5 (ru) | ||
RU2011104360A (ru) | Фармацевтические соединения, содержащие 5-хлор-n-({(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)-фенил]-1,3-оксазолидин-5-ил}-митил)-2-тиофенкарбоксамид | |
JP2012158592A5 (ru) | ||
RU2008116831A (ru) | Твердые применяемые орально фармацевтические формы применения с быстрым высвобождением активного вещества | |
JP2011527704A5 (ru) | ||
RU2019126797A (ru) | Составы твердых дозированных лекарственных форм антагониста орексинового рецептора | |
RU2015117251A (ru) | Новые соединения | |
CO5611118A2 (es) | Formulaciones de azitromicina granuladas por via seca | |
RU2014101227A (ru) | Композиция покрытия, подходящая для фармацевтических или нутрицевтических лекарственных форм | |
JP2011225600A5 (ru) | ||
JP2006528221A5 (ru) | ||
CY1114499T1 (el) | Βιοδιαθεσιμες στερεες δοσολογικες μορφες μεταξαλονης | |
RU2015116953A (ru) | Новые соединения | |
RU2013141534A (ru) | Составы l-ментола, состоящие из множества частиц, и связанные с ними способы | |
RU2019123406A (ru) | Технология приготовления таблеток для cgrp-активных соединений | |
JP2013505233A5 (ru) | ||
RU2008114841A (ru) | Фармацевтическая композиция, способная индуцировать защитный иммунный ответ против вируса денге, содержащая капсидный белок этого вируса | |
RU2017144574A (ru) | Пероральная композиция целекоксиба для лечения боли | |
NZ594669A (en) | Oral composition of Vorinostat | |
RU2010119929A (ru) | Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины | |
RU2019132074A (ru) | Новая аморфная дисперсия (5-{ 5-[n'-(2-хлор-6-метилбензоил)гидразинокарбонил]-2-метил-фенилэтинил} -пиридин-2-ил)амида циклопропанкарбоновой кислоты | |
EA201892778A1 (ru) | Фармацевтическая композиция для перорального введения с улучшенной однородностью состава, содержащая пеллеты с замедленным высвобождением, содержащие тамсулозина гидрохлорид | |
ES2625012T3 (es) | Producto de comicronización que comprende un modulador selectivo del receptor de progesterona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HE9A | Changing address for correspondence with an applicant |